Hoelscher Paul W. 4
4 · Horizon Therapeutics Public Ltd Co · Filed Mar 25, 2022
Insider Transaction Report
Form 4
Hoelscher Paul W.
EVP, Finance
Transactions
- Exercise/Conversion
Ordinary Shares
2022-03-23$15.96/sh+26,090$416,396→ 27,139 total - Sale
Ordinary Shares
2022-03-23$110.01/sh−11,699$1,287,018→ 160,527 total(indirect: By LLC) - Sale
Ordinary Shares
2022-03-25$110.00/sh−663$72,930→ 158,383 total(indirect: By LLC) - Gift
Ordinary Shares
2022-03-07−66,626→ 1,049 total - Gift
Ordinary Shares
2022-03-07+66,626→ 245,015 total(indirect: By Trust) - Sale
Ordinary Shares
2022-03-23$110.00/sh−26,090$2,870,002→ 1,049 total - Sale
Ordinary Shares
2022-03-24$110.00/sh−1,481$162,910→ 159,046 total(indirect: By LLC) - Gift
Ordinary Shares
2022-03-07−172,226→ 72,789 total(indirect: By Trust) - Gift
Ordinary Shares
2022-03-07+172,226→ 172,226 total(indirect: By LLC) - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-23−26,090→ 30,275 totalExercise: $15.96Exp: 2024-06-26→ Ordinary Shares (26,090 underlying)
Footnotes (5)
- [F1]These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.115 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021.
- [F5]The option is fully vested and exercisable.